Expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in neoplasms of dogs and cats
BACKGROUND: Receptor activator of nuclear factor kappa-B (RANK), RANK-ligand (RANKL), and the soluble decoy receptor osteoprotegerin (OPG) form a key axis modulating osteoclastogenesis. In health, RANKL-expressing bone stromal cells and osteoblasts activate osteoclasts through RANK ligation, resulting in homeostatic bone resorption. Skeletal tumors of dogs and cats, whether primary or metastatic, may express RANKL and directly induce malignant osteolysis.
HYPOTHESIS: Bone malignancies of dogs and cats may express RANKL, thereby contributing to pathologic bone resorption and pain. Furthermore, relative RANKL expression in bone tumors may correlate with radiographic characteristics of bone pathology.
ANIMALS: Forty-two dogs and 6 cats with spontaneously-occurring tumors involving bones or soft tissues were evaluated.
METHODS: A polyclonal anti-human RANKL antibody was validated for use in canine and feline cells by flow cytometry and immunocytochemistry. Fifty cytologic specimens were collected from bone and soft tissue tumors of 48 tumor-bearing animals and assessed for RANKL expression. In 15 canine osteosarcoma (OSA) samples, relative RANKL expression was correlated with radiographic characteristics of bone pathology.
RESULTS: Expression of RANKL by neoplastic cells was identified in 32/44 canine and 5/6 feline tumor samples. In 15 dogs with OSA, relative RANKL expression did not correlate with either radiographic osteolysis or bone mineral density as assessed by dual energy x-ray absorptiometry.
CONCLUSIONS AND CLINICAL IMPORTANCE: In dogs and cats, tumors classically involving bone and causing pain, often may express RANKL. Confirming RANKL expression in tumors is a necessary step toward the rational institution of novel therapies targeting malignant osteolysis via RANKL antagonism.
| Errataetall: | |
|---|---|
| Medienart: |
Artikel |
| Erscheinungsjahr: |
2007 |
|---|---|
| Erschienen: |
2007 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Journal of veterinary internal medicine - 21(2007), 1 vom: 14. Jan., Seite 133-40 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barger, Anne M [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 11.04.2007 Date Revised 13.05.2019 published: Print ErratumIn: J Vet Intern Med. 2007 Mar-Apr;21(2):viii Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM168768321 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM168768321 | ||
| 003 | DE-627 | ||
| 005 | 20231223115838.0 | ||
| 007 | tu | ||
| 008 | 231223s2007 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0563.xml |
| 035 | |a (DE-627)NLM168768321 | ||
| 035 | |a (NLM)17338161 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barger, Anne M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in neoplasms of dogs and cats |
| 264 | 1 | |c 2007 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 11.04.2007 | ||
| 500 | |a Date Revised 13.05.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: J Vet Intern Med. 2007 Mar-Apr;21(2):viii | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Receptor activator of nuclear factor kappa-B (RANK), RANK-ligand (RANKL), and the soluble decoy receptor osteoprotegerin (OPG) form a key axis modulating osteoclastogenesis. In health, RANKL-expressing bone stromal cells and osteoblasts activate osteoclasts through RANK ligation, resulting in homeostatic bone resorption. Skeletal tumors of dogs and cats, whether primary or metastatic, may express RANKL and directly induce malignant osteolysis | ||
| 520 | |a HYPOTHESIS: Bone malignancies of dogs and cats may express RANKL, thereby contributing to pathologic bone resorption and pain. Furthermore, relative RANKL expression in bone tumors may correlate with radiographic characteristics of bone pathology | ||
| 520 | |a ANIMALS: Forty-two dogs and 6 cats with spontaneously-occurring tumors involving bones or soft tissues were evaluated | ||
| 520 | |a METHODS: A polyclonal anti-human RANKL antibody was validated for use in canine and feline cells by flow cytometry and immunocytochemistry. Fifty cytologic specimens were collected from bone and soft tissue tumors of 48 tumor-bearing animals and assessed for RANKL expression. In 15 canine osteosarcoma (OSA) samples, relative RANKL expression was correlated with radiographic characteristics of bone pathology | ||
| 520 | |a RESULTS: Expression of RANKL by neoplastic cells was identified in 32/44 canine and 5/6 feline tumor samples. In 15 dogs with OSA, relative RANKL expression did not correlate with either radiographic osteolysis or bone mineral density as assessed by dual energy x-ray absorptiometry | ||
| 520 | |a CONCLUSIONS AND CLINICAL IMPORTANCE: In dogs and cats, tumors classically involving bone and causing pain, often may express RANKL. Confirming RANKL expression in tumors is a necessary step toward the rational institution of novel therapies targeting malignant osteolysis via RANKL antagonism | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a RANK Ligand |2 NLM | |
| 700 | 1 | |a Fan, Timothy M |e verfasserin |4 aut | |
| 700 | 1 | |a de Lorimier, Louis-Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Sprandel, Ian T |e verfasserin |4 aut | |
| 700 | 1 | |a O'Dell-Anderson, Kristen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of veterinary internal medicine |d 1996 |g 21(2007), 1 vom: 14. Jan., Seite 133-40 |w (DE-627)NLM012980854 |x 1939-1676 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2007 |g number:1 |g day:14 |g month:01 |g pages:133-40 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2007 |e 1 |b 14 |c 01 |h 133-40 | ||